Home/Filings/4/0001615993-25-000005
4//SEC Filing

Dayno Jeffrey M. 4

Accession 0001615993-25-000005

CIK 0001802665other

Filed

Dec 16, 7:00 PM ET

Accepted

Dec 17, 5:25 PM ET

Size

10.6 KB

Accession

0001615993-25-000005

Insider Transaction Report

Form 4
Period: 2025-12-12
Dayno Jeffrey M.
DirectorPRESIDENT, CEO
Transactions
  • Exercise/Conversion

    Common Stock

    2025-12-12$8.22/sh+20,000$164,40020,000 total
  • Sale

    Common Stock

    2025-12-12$40.11/sh20,000$802,1460 total
  • Sale

    Common Stock

    2025-12-12$40.11/sh5,933$237,9570 total
  • Exercise/Conversion

    Stock Option

    2025-12-1220,0000 total
    Exercise: $8.22Exp: 2027-11-13Common Stock (20,000 underlying)
Footnotes (3)
  • [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.28. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F3]The stock option vests in five equal annual installments beginning on November 1, 2018.

Issuer

Harmony Biosciences Holdings, Inc.

CIK 0001802665

Entity typeother

Related Parties

1
  • filerCIK 0001615993

Filing Metadata

Form type
4
Filed
Dec 16, 7:00 PM ET
Accepted
Dec 17, 5:25 PM ET
Size
10.6 KB